Aisling Capital
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by
Business Model:
Revenue: $15.1M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Aisling Capital Information
Geographic Data
Address: 888 7th Ave
City: New York
State: NY
Zip: 10106
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$423M
Social
Twitter
Linkedin
Crunchbase
Metrics
2,323,328Website Global Rank
8,065Website Monthly Traffic
Twitter Followers
Description
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
Contact Phone:
+12126516380
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 4/2004 | Cardiokine | Series A | 37M |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 7/2012 | Agile Therapeutics | Series C | 0 |
| 3/2015 | Aimmune Therapeutics | Series B | 80M |
| 4/2013 | Esperion | Venture Round | 33M |
| 9/2022 | Forge Biologics | Series C | 0 |
| 1/2016 | Syros Pharmaceuticals | Series C | 40M |
| 5/2013 | ViewRay | Venture Round | 15M |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 10/2019 | Nuvation Bio | Series A | 275M |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 3/2015 | Cynapsus Therapeutics | Venture Round | 16.6M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 6/2017 | Earlens | Series C | 0 |
| 10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 4/2019 | Ajax Health | Series C | 85M |
| 4/2016 | PowerVision | Series D | 10M |
| 1/2015 | LENSAR, Inc. | Private Equity Round | 16M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 6/2009 | Cempra | Series C | 46M |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 6/2016 | Aclaris Therapeutics | Post-IPO Equity | 20M |
| 4/2006 | Cempra | Series A | 22M |
| 12/2016 | Prolacta Bioscience | Venture Round | 0 |
| 3/2013 | T2 Biosystems | Series E | 40M |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 5/2002 | Advion Inc. | Series B | 15M |
| 10/2014 | Syros Pharmaceuticals | Series B | 53M |
| 8/2014 | Dermira | Series C | 51M |
| 7/2013 | Versartis | Series C | 0 |
| 12/2007 | Topaz Pharmaceuticals Inc | Series A | 20M |
| 5/2014 | Loxo Oncology | Series B | 24M |
| 6/2016 | Earlens | Series C | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 1/2013 | Versartis | Series C | 0 |
| 4/2012 | PreCision Dermatology | Venture Round | 29.4M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 2/2011 | Pharmaron | Series C | 40M |
| 1/2008 | ViewRay | Series B | 25M |
| 12/2013 | ViewRay | Venture Round | 0 |
| 3/2012 | ViewRay | Series C | 45M |
| 2/2014 | Versartis | Series E | 55M |
| 10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
| 6/2016 | F2G | Series E | 60M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 6/2019 | Ajax Health | Series C | 15M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 10/2007 | Paratek Pharmaceuticals | Post-IPO Equity | 40M |
| 4/2014 | Earlens | Series B | 40M |
| 9/2011 | ViewRay | Debt Financing | 10M |
| 8/2010 | ViewRay | Series C | 20M |
| 2/2012 | ADMA Biologics | Venture Round | 0 |
| 8/2012 | Intercept Pharmaceuticals | Series C | 30M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 7/2007 | Xanodyne | Series A | 25M |
| 4/2007 | Sirion Therapeutics | Series B | 45M |
| 4/2018 | Zosano Pharma | Post-IPO Equity | 50M |
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 7/2020 | Elevation Oncology | Series A | 32.5M |
| 7/2021 | Wugen | Series B | 0 |
| 4/2007 | Natural Dentist | Series B | 13.2M |
| 1/2017 | Ajax Health | Series A | 95M |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 10/2013 | Versartis | Series D | 0 |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 7/2014 | Paratek Pharmaceuticals | Post-IPO Debt | 93M |
| 1/2012 | Roka Bioscience | Series D | 47.5M |
| 1/2002 | Allos Therapeutics | Private Equity Round | - |
| 10/2013 | LENSAR, Inc. | Debt | 60M |
| 6/2014 | PowerVision | Series D | 30M |
| 6/2007 | BioRelix | Series A | 25.8M |
| 9/2008 | Bridge Pharmaceuticals | Series B | 53.3M |
| 10/2013 | LENSAR, Inc. | Equity | 27M |
| 5/2008 | Esperion | Series A | 22.8M |
| 4/2015 | Spirox | Series B | 18.5M |
| 3/2012 | LENSAR, Inc. | Venture Round | 24M |
| 3/2016 | Spirox | Series C | 45M |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 9/2018 | Atreca | Series C | 125M |
| 10/2013 | Loxo Oncology | Series A | 33M |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 7/2007 | Cempra | Series B | 0 |
| 7/2018 | Ajax Health | Series B | 120M |
| 7/2015 | ViewRay | Post-IPO Equity | 0 |
| 2/2015 | Agile Therapeutics | Post-IPO Equity | 0 |
| 11/2012 | Ambit Biosciences | Venture Round | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 3/2017 | Promentis Pharmaceuticals | Series C | 26M |
| 6/2016 | Miramar Labs | Venture Round | - |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 8/2011 | T2 Biosystems | Series D | 0 |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 4/2010 | Aragon Pharmaceuticals, Inc. | Series B | 22M |
| 9/2017 | GTx | Post-IPO Equity | 48.5M |
| 10/2018 | Earlens | Series D | 0 |
| 11/2015 | ObsEva | Series B | 60M |
| 10/2013 | Seragon Pharmaceuticals | Series A | 30M |
| 2/2012 | CeNeRx BioPharma | Series D | 4.6M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 10/2014 | Miramar Labs | Series D | 26M |
| 2/2018 | Avrobio | Series B | 60M |
| 4/2007 | Bioenvision | Venture Round | 7.4M |
| 3/2012 | Cytos | Post-IPO Equity | 40M |
| 6/2022 | Dren Bio | Series B | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 9/2021 | Garuda Therapeutics | Series A | 0 |
| 7/2021 | Wugen | Series B | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 1/2021 | Biomea Fusion | Series A | 0 |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 11/2020 | Elevation Oncology | Series B | 0 |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
